About Peptide News Network
Peer-reviewed peptide science, regulation, and industry — reported at the source and translated for a general audience.
Our mission
Peptide News Network covers the fast-moving world of peptide medicine: new research, clinical-trial results, FDA and regulatory decisions, and the companies shaping the field. Our aim is to translate the peer-reviewed and regulatory record into plain language without flattening the science that matters. Every news story cites its primary sources — papers, trial registries, FDA documents, and filings — so readers can check our work.
How we report
We organize coverage into four newsroom sections — Research, Clinical Trials, Regulation, and Industry — plus an Explainers series for foundational science and a research library of evergreen compound overviews. Compounds in the library are sorted into four evidence tiers by the strength of their published evidence and their regulatory standing, never by popularity. A tier is a reading aid, not a verdict.
When new evidence changes a story, we update it and mark the revision date. Corrections are made promptly and transparently; if you spot an error, tell us and we will fix it. Our full editorial standards — sourcing, fact-checking, corrections, and how our content is produced — are documented separately.
The site is written and edited by Ian Gauntt, RN, BSN, founder and editor. He is a registered nurse with nearly a decade of critical care experience; his clinical background informs how the reporting reads the evidence. Even so, the Site is journalism and education — not individualized medical advice. See the disclaimer below.
Ownership and funding
Peptide News Network is an independent publication operated by Biosignal Media. We are not a pharmacy, clinic, laboratory, or seller of any compound, and we do not endorse any product, vendor, or protocol. Our reporting is editorially independent of any company or product we cover.
Contact
Story tips, corrections, and questions are welcome at hello@peptidenewsnetwork.com. You can also follow new stories through our RSS feed.